Drug & intervention

leuprolide

RxCUI 42375

Clinical trials40
Recruiting7
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Leuprorelin

Leuprorelin, also known as leuprolide, is a manufactured version of a hormone used to treat prostate cancer, breast cancer, endometriosis, uterine fibroids, for early puberty, as part of transgender hormone therapy, or to perform chemical castration of violent sex offenders. It is given by injection into a muscle or under the skin. Leuprorelin is in the gonadotropin-releasing hormone (GnRH) analogue family of medications. It works by decreasing gonadotropins, thereby decreasing testosterone and estradiol. Common side effects include hot flashes, unstable mood, trouble sleeping, headaches, and pain at the site of injection. Other side effects may include high blood sugar, allergic reactions, and problems with the pituitary gland. Use during pregnancy may harm foetal development. Leuprorelin was patented in 1973 and approved for medical use in the United States in 1985. It is on the World Health Organization's List of Essential Medicines. It is sold under the brand name Lupron, among others.

Read on Wikipedia ↗ Wikidata Q907160 ↗
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

40 shown
Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CTNCT07455903 · 2026-07-29
RECRUITING
Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS TrialNCT07158021 · 2026-01-22
RECRUITING
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac TrialNCT06650579 · 2025-01-31
RECRUITING
Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate CancerNCT06330805 · 2024-08-12
RECRUITING
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE TrialNCT06378866 · 2024-06-03
RECRUITING
Phase IIIb Study of Ribociclib + ET in Early Breast CancerNCT05827081 · 2024-02-28
RECRUITING
RecoverPC: Relugolix vs GnRH Agonist in Quality of LifeNCT05765500 · 2024-02-12
RECRUITING
RElugolix VErsus LeUprolide Cardiac TrialNCT05320406 · 2022-06-06
ACTIVE_NOT_RECRUITING
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialNCT05050084 · 2021-12-06
ACTIVE_NOT_RECRUITING
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialNCT04513717 · 2021-01-21
ACTIVE_NOT_RECRUITING
A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate CancerNCT04194554 · 2020-11-06
ACTIVE_NOT_RECRUITING
Prediction of the PRONOUNCE Prostate Cancer Trial in Healthcare Claims DataNCT04897958 · 2019-09-21
COMPLETED
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate CancerNCT03298087 · 2018-07-01
COMPLETED
Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen ExcessNCT01422096 · 2018-06-01
WITHDRAWN
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior TreatmentsNCT03056755 · 2017-08-29
COMPLETED
A Study of ELIGARD® in Hormone-dependent Prostate Cancer PatientsNCT03035032 · 2017-06-23
COMPLETED
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by SurgeryNCT03070886 · 2017-04-05
ACTIVE_NOT_RECRUITING
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBCNCT02941926 · 2016-11-30
COMPLETED
Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing ProstatectomyNCT02903368 · 2016-10-19
COMPLETED
Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial)NCT02543255 · 2016-09-01
COMPLETED
AASUR in High Risk Prostate CancerNCT02772588 · 2016-05-12
COMPLETED
A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular DiseaseNCT02663908 · 2016-04-19
TERMINATED
Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young WomenNCT02914158 · 2016-03-30
UNKNOWN
Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate CancerNCT02508636 · 2015-12-22
TERMINATED
Micro RNAs to Predict Response to Androgen Deprivation TherapyNCT02366494 · 2015-04-29
COMPLETED
Testosterone Regulation of the Natriuretic Peptide SystemNCT02269072 · 2015-02-01
WITHDRAWN
Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the ProstateNCT02064036 · 2013-06-06
COMPLETED
Bipolar Androgen-based Therapy for Prostate Cancer (BAT)NCT01750398 · 2013-01-01
COMPLETED
Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate CancerNCT01547299 · 2012-03-31
COMPLETED
Ipilimumab + Androgen Depravation Therapy in Prostate CancerNCT01377389 · 2011-06-17
TERMINATED
Influence of Male Hormones on Regional Fat MetabolismNCT01160328 · 2010-06-01
COMPLETED
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate CancerNCT00924469 · 2009-11-01
COMPLETED
A Study of Degarelix in Patients With Prostate CancerNCT00928434 · 2009-05-01
COMPLETED
Extended Endocrine Therapy for Premenopausal Women With Breast CancerNCT00903162 · 2009-05-01
COMPLETED
Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate CancerNCT00631527 · 2008-02-01
COMPLETED
Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate CancerNCT00521781 · 2007-08-01
TERMINATED
A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)NCT00514917 · 2007-07-01
TERMINATED
External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate CancerNCT00388804 · 2005-02-01
TERMINATED
Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate CancerNCT00500110 · 2003-06-01
COMPLETED
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate CancerNCT00028769 · 2001-12-01
COMPLETED

Conditions being studied

Prostate Cancer18Breast Cancer4Prostatic Neoplasms4Prostate Adenocarcinoma3Stage III Prostate Cancer AJCC v83Biochemically Recurrent Prostate Carcinoma2Localized Prostate Carcinoma2Obesity2Recurrent Prostate Cancer2Stage IIB Prostate Cancer AJCC v82Stage IIC Prostate Cancer AJCC v82Stage IVA Prostate Cancer AJCC v82Adenocarcinoma of the Prostate1Anatomic Stage I Breast Cancer AJCC v81Anatomic Stage II Breast Cancer AJCC v81Anatomic Stage III Breast Cancer AJCC v81Anatomic Stage IV Breast Cancer AJCC v81Castration-resistant Prostate Cancer1Early Breast Cancer1Hyperandrogenemia1

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.